FYB201 (Ranibizumab biosimilar) / YESAFILI®
Neovascular (wet) Age-related Macular Degeneration (AMD), Diabetic Macular Edema (DME), Myopic Choroidal Neovascularization (mCNV)
Key Facts
About Formycon AG
Formycon AG is a Germany-based, publicly traded biopharmaceutical company dedicated to the development of biosimilars and innovative biologics. Its core expertise lies in the complex process development, analytical characterization, and manufacturing of protein therapeutics, with a robust pipeline targeting high-value markets. The company's strategy combines in-house development of key assets with strategic collaborations, such as its partnership with Bioeq AG, to advance products through clinical development and commercialization. Formycon's focus on high-quality, cost-effective alternatives to originator biologics positions it within the growing global biosimilars market.
View full company profile